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mediciNe & HealtH/RHode iSlaNd
the long-term objeCtIve of our reSearCh 
program is to understand how bile acid 
homeostasis is regulated in physiological 
as well as pathological conditions, with a 
focus on the transcriptional regulation of 
the bile salt export pump (BSEP).
As one of the major constituents of 
bile, bile acids were once considered bodily 
waste with no useful functions. Now it is 
well established that bile acids have impor-
tant physiological functions in animals and 
human.1 First, the well-known function of 
bile acids is to solubilize cholesterol and 
lipids in an aqueous environment, such as 
in the bile and the intestines. On the other 
hand, as biological detergents, too much 
bile acids are toxic for cells. Second, bile 
acids are recognized as signaling molecules 
serving as the endogenous ligands for nu-
clear receptor farnesoid x receptor (FXR) 
and G-protein-coupled receptor TGR5 to 
regulate cholesterol, bile acids and glucose 
homeostasis. Finally, recent studies have 
extended the functions of bile acids into 
various non-metabolic areas including 
inflammation, liver regeneration, hepa-
tocarcinogenesis, inhibition of intestine 
bacterial growth and colon cancer. 
Bile acid homeostasis is achieved 
through coordinately regulated bile acid 
synthesis and elimination pathways. 
Cholesterol 7α-hydroxylase (CYP7A1) 
is the rate-limiting enzyme for bile acid 
synthesis while BSEP is the rate limiting-
step in the enterohepatic circulation of 
bile acids.2 (Figure 1) Modulation of 
BSEP expression or function by inherited 
or acquired factors has profound impacts 
on bile acid homeostasis and subsequently 
contributes to the risk for various bile 
acids-associated diseases, including intra-
hepatic cholestasis, gallstone disease and 
hepatocellular carcinoma (HCC). Study-
ing the transcriptional regulation of BSEP 
will uncover the mechanistic insights in 
the role BSEP plays in physiological as 
well as pathological conditions.
BSeP expression is regulated by 
nuclear receptor liver receptor 
homolog 1 (lRH-1) and oxysterols. 
The expression of BSEP is positively 
regulated by the bile acid/FXR signal-
ing pathway.3 Activation of FXR by bile 
acids strongly induces BSEP expression 
in vitro and in vivo. Such feed-forward 
regulation of BSEP by FXR is considered 
a major mechanism for preventing exces-
sive accumulation of toxic bile acids in 
hepatocytes. 
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Figure. 1. Enterohepatic circulation of bile acids. Bile acids are synthesized in the liver from cholesterol, secreted into the bile through 
BSEP, reabsorbed in the intestine, and return to the liver via the portal vein. In the liver, bile acids are taken up through Na+/taurocholate 
cotransporting polypeptide (NTCP) and re-secreted into bile through BSEP, completing the enterohepatic circulation. Through each cycle, 
95% bile acids are reabsorbed in the intestine while 5% bile acids are eliminated through fecal excretion.
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In addition to the FXR signaling 
pathway, we have shown that BSEP is 
transcriptionally regulated by another 
nuclear receptor liver receptor homolog 
1 (LRH-1). LRH-1 activated the BSEP 
promoter during transcription and func-
tioned as a modulator in the bile acid/
FXR-mediated BSEP regulation. Our 
findings suggest that LRH-1 plays a sup-
porting role with FXR in maintaining 
hepatic bile acid levels by coordinately 
regulating CYP7A1 and BSEP for bile 
acid synthesis and elimination, respec-
tively.4
Oxysterols, oxidized derivatives of 
cholesterol, serve as endogenous ligands 
for nuclear receptor liver x receptor (LXR) 
to regulate cholesterol homeostasis. We 
discovered that oxysterols can also acts 
as FXR ligands and induce BSEP expres-
sion.5 This finding demonstrates that 
oxysterols function as dual ligands for 
both LXR and FXR, and are potentially 
involved in regulating the biosynthesis, 
transport and disposition of cholesterol 
as well as bile acids.
modulation of BSeP expression 
by xenobiotics has therapeutic or 
toxicological effects.
As the rate-limiting step in bile acid 
disposition, modulation of BSEP expres-
sion by xenobiotics, such as drugs and 
natural products, significantly impacts 
cholesterol metabolism and intrahepatic 
bile acid levels. Guggulsterone is a natural 
product from the Commiphora mukul tree 
and has been used by humans for over 
several thousands of years. However, the 
underlying mechanism is unknown. We 
found that guggulsterone synergistically 
up-regulates BSEP expression with bile 
acids and subsequently promotes conver-
sion of cholesterol into bile acids.6 Such 
up-regulation of BSEP expression by gug-
gulsterone represents a possible mecha-
nism for the guggulsterone-mediated 
hypolipidemic effect.
BSeP expression is severely 
diminished in patients with 
hepatocellular carcinoma (Hcc) 
associated with altered FXR 
isoform expression.
A genetic defect of BSEP leads to 
severe cholestasis and HCC in young 
children. Clinical studies showed that 
bile acid homeostasis is disrupted in HCC 
patients with elevated serum bile acid level 
as a proposed marker for HCC.7 However, 
the underlying mechanisms remain largely 
unknown. In our study, we found that 
BSEP expression was severely diminished 
in HCC patients and was associated 
with altered FXR isoform (FXRα1 and 
FXRα2) expression. Further studies 
showed that proinflammatory cytokines 
interleukin-6 (IL-6) and tumor necrosis 
factor-alpha (TNF-α) were significantly 
elevated in HCC tissues. Treatment of 
hepatoma Huh 7 cells with IL-6 and 
TNF-α resulted in a marked alteration in 
FXR isoform expression concurrent with 
a significant decrease in BSEP expression. 
Thus restoration of BSEP expression 
through suppressing inflammation in the 
liver may re-establish the bile acid ho-
meostasis with beneficial effects in HCC 
patients (submitted for publication). 
cross-talking between bile acid 
and estrogen signaling pathway 
in the induction of intrahepatic 
cholestasis of pregnancy (icP) and 
gallstone disease (Gd). 
Among diseases resulting from the 
imbalance of bile acid levels, ICP and 
GD are both associated with estrogen.8 
Although multiple risk factors are linked 
to those disorders, studies have demon-
strated that estrogen may play a key role 
in the induction of the two diseases. Our 
research program is directly aimed at 
investigating the underlying mechanism 
for the two distinct but related diseases. 
We showed that estrogen repressed human 
BSEP expression in vitro and in vivo, and 
the repression was mediated by estrogen 
receptor α (ERα) through physically in-
teracting with FXR, indicating a crosstalk 
between estrogen/ERα and bile acids/
FXR signaling pathway (unpublished 
results). We plan to test the hypothesis 
that down-regulation of BSEP expression 
by estrogen is mediated through a novel 
non-classical transrepression pathway, a 
direct interaction between ERα and FXR, 
and as a consequence is a common risk 
factor for ICP and GD. 
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